CRBP
Price
$8.35
Change
+$0.96 (+12.99%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
102.14M
SKYE
Price
$1.81
Change
+$0.08 (+4.62%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
55.44M
Ad is loading...

CRBP vs SKYE

Header iconCRBP vs SKYE Comparison
Open Charts CRBP vs SKYEBanner chart's image
Corbus Pharmaceuticals Holdings
Price$8.35
Change+$0.96 (+12.99%)
Volume$2.15K
Capitalization102.14M
Skye Bioscience
Price$1.81
Change+$0.08 (+4.62%)
Volume$19.32K
Capitalization55.44M
CRBP vs SKYE Comparison Chart
Loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBP vs. SKYE commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Buy and SKYE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CRBP: $8.35 vs. SKYE: $1.79)
Brand notoriety: CRBP and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 128% vs. SKYE: 38%
Market capitalization -- CRBP: $102.14M vs. SKYE: $55.44M
CRBP [@Biotechnology] is valued at $102.14M. SKYE’s [@Biotechnology] market capitalization is $55.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 1 green, 4 red.
According to our system of comparison, SKYE is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 3 TA indicator(s) are bullish while SKYE’s TA Score has 6 bullish TA indicator(s).

  • CRBP’s TA Score: 3 bullish, 5 bearish.
  • SKYE’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than CRBP.

Price Growth

CRBP (@Biotechnology) experienced а +38.47% price change this week, while SKYE (@Biotechnology) price change was +24.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

CRBP is expected to report earnings on Mar 11, 2025.

SKYE is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRBP($102M) has a higher market cap than SKYE($55.4M). SKYE (-36.749) and CRBP (-37.373) have similar YTD gains . SKYE has higher annual earnings (EBITDA): -19.64M vs. CRBP (-37.75M). CRBP has more cash in the bank: 149M vs. SKYE (67.4M). SKYE has less debt than CRBP: SKYE (191K) vs CRBP (3.24M). CRBP (0) and SKYE (0) have equivalent revenues.
CRBPSKYECRBP / SKYE
Capitalization102M55.4M184%
EBITDA-37.75M-19.64M192%
Gain YTD-37.373-36.749102%
P/E RatioN/A3.57-
Revenue00-
Total Cash149M67.4M221%
Total Debt3.24M191K1,696%
FUNDAMENTALS RATINGS
CRBP vs SKYE: Fundamental Ratings
CRBP
SKYE
OUTLOOK RATING
1..100
2987
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
6596
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKYE's Valuation (33) in the null industry is in the same range as CRBP (54) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's SMR Rating (94) in the null industry is in the same range as CRBP (94) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

CRBP's Price Growth Rating (65) in the Biotechnology industry is in the same range as SKYE (96) in the null industry. This means that CRBP’s stock grew similarly to SKYE’s over the last 12 months.

SKYE's P/E Growth Rating (96) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPSKYE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend about 1 month ago
86%
Declines
ODDS (%)
Bearish Trend 24 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FUUFF0.140.01
+8.05%
F3 URANIUM CORP. NEW
DRCR0.05N/A
+6.20%
Dear Cashmere Holding Co.
ASCCY20.910.77
+3.85%
Asics Corp.
OVCHY25.260.36
+1.45%
Overseas Chinese Banking Corp., Ltd.
IPXHY12.67-0.41
-3.13%
Inpex Corp.

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
+10.46%
SKYE - CRBP
46%
Loosely correlated
+14.57%
FBIO - CRBP
36%
Loosely correlated
+3.27%
APLS - CRBP
35%
Loosely correlated
+0.69%
STOK - CRBP
34%
Loosely correlated
+3.25%
PMCB - CRBP
31%
Poorly correlated
+3.93%
More